Celgene Corporation (NASDAQ:CELG) gets downgraded to Neutral by Atlantic Securities

Analyst Ratings For Celgene Corporation (NASDAQ:CELG)

Story continues below

Today, Celgene Corporation (NASDAQ:CELG) stock was downgraded by Atlantic Securities from Overweight to Neutral.

There are 14 Hold Ratings, 10 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Celgene Corporation (NASDAQ:CELG) is Hold with a consensus target price of $100.50 per share, a potential 6.53% upside.

Some recent analyst ratings include

  • 4/1/2019-Celgene Corporation (NASDAQ:CELG) gets downgraded to Neutral by Atlantic Securities
  • 4/1/2019-Celgene Corporation (NASDAQ:CELG) gets downgraded to Neutral by UBS Group
  • 4/1/2019-Celgene Corporation (NASDAQ:CELG) gets downgraded to Market Perform by William Blair
  • 2/26/2019-Celgene Corporation (NASDAQ:CELG) has coverage initiated with a Market Perform rating and $102.00 price target
  • 2/1/2019-Celgene Corporation (NASDAQ:CELG) gets downgraded to Hold by Jefferies Financial Group with a price target of $95.00
  • 1/31/2019-Celgene Corporation (NASDAQ:CELG) had its Buy rating reiterated by Cantor Fitzgerald with a $100.00 price target
  • 1/4/2019-Celgene Corporation (NASDAQ:CELG) gets upgraded to Outperform by Robert W. Baird with a price target of $92.00
  • On 2/12/2019 Ernest Mario, Director, bought 2,000 with an average share price of $89.99 per share and the total transaction amounting to $179,980.00.
  • On 2/7/2019 James J Loughlin, Director, sold 23,466 with an average share price of $87.29 per share and the total transaction amounting to $2,048,347.14.
  • On 8/9/2018 Ernest Mario, Director, sold 12,000 with an average share price of $92.32 per share and the total transaction amounting to $1,107,840.00.
  • On 8/7/2018 John H Weiland, Director, bought 5,575 with an average share price of $89.73 per share and the total transaction amounting to $500,244.75.
  • On 6/7/2018 Michael D Casey, Director, sold 13,000 with an average share price of $78.77 per share and the total transaction amounting to $1,024,010.00.
  • On 6/4/2018 James J Loughlin, Director, sold 17,750 with an average share price of $78.96 per share and the total transaction amounting to $1,401,540.00.
  • On 5/18/2018 Gilla Kaplan, Director, sold 27,750 with an average share price of $78.66 per share and the total transaction amounting to $2,182,815.00.

About Celgene Corporation (NASDAQ:CELG)
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA to treat various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaborations with Skyhawk Therapeutics, Inc., Dragonfly Therapeutics, Inc., Obsidian Therapeutics, Philogen S.p.A., and Kyn Therapeutics. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Recent Trading Activity for Celgene Corporation (NASDAQ:CELG)
Shares of Celgene Corporation closed the previous trading session at 94.34 up +6.89 7.88% with 43366400 shares trading hands.

An ad to help with our costs